IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis

Archives of Medical Science

Volumn 7, Issue 6, 2011, Pages 984-992

  Athyros, Vasilios G ^a   Hatzitolios, Apostolos I ^a   Karagiannis, Asterios ^a   Savopoulos, Christos ^a   Katsiki, Niki ^a   Tziomalos, Konstantinos ^a   Papagianni, Aikaterini ^a   Kakafika, Anna ^b   Gossios, Thomas D ^c   Mikhailidis, Dimitri P ^d  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Euro Clinic   (Greece)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Diabetes mellitus; Dyslipidaemia; Hypertension; Metabolic syndrome; Multifactorial intervention; Renal function; Statin; Uric acid

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; INSULIN; METFORMIN; SULFONYLUREA; URIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; URIC ACID BLOOD LEVEL;

EID: 84855392114     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/AOMS.2011.26610     Document Type: Article

References (58)

1. Chronic Kidney Disease (CKD). National Kidney Foundation. Available at: http://www.kidney.org/kidneyDisease/ckd/index.cfm. Accessed August 6, 2011.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (suppl 1): S1-266.
3. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-47. (Pubitemid 350074801)
4. Levey AS, Coresh J, Balk E, et al.; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
5. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12. (Pubitemid 36043346)
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
7. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.
8. Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008; 6: 93-107.
9. Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008; 167: 1226-34. (Pubitemid 351670638)
10. Tziomalos K, Ganotakis ES, Gazi IF, Nair DR, Mikhailidis DP. Kidney function and estimated vascular risk in patients with primary dyslipidemia. Open Cardiovasc Med J 2009 16; 3: 57-68.
11. Black C, Sharma P, Scotland G, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess 2010; 14: 1-184.
12. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34. (Pubitemid 38901488)
13. Athyros VG, Elisaf M, Papageorgiou AA, et al.; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-99. (Pubitemid 38401873)
14. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27. (Pubitemid 46050336)
15. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP; GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003; 19: 615-7. (Pubitemid 37288068)
16. Athyros VG, Karagiannis A, Kakafika A, Elisaf M, Mikhailidis DP. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant 2007; 22: 963-4. (Pubitemid 46351732)
17. Athyros VG, Karagiannis A, Ganotakis ES, et al.; for the Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin doi:10.1185/03007995.2011.595782.
18. Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908-15. (Pubitemid 27379464)
19. Baigent C, Landray MJ, Reith C, et al.; the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-92.
20. Hatzitolios AI, Athyros VG, Karagiannis A, et al.; IMPROVE Collaborative Group. Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol 2009; 134: 322-9.
21. Athyros VG, Karagiannis A, Hatzitolios AI, et al.; SAGEMETS collaborative group. Standardized arrangement fora guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009; 25: 971-80.
22. Karagiannis A, Hatzitolios AI, Athyros VG, et al. Implementation of guidelines for the management of arterial hypertension. The IMPULSION study. Open Cardiovasc Med J 2009; 3: 26-34.
23. Athyros VG, Hatzitolios A, Karagiannis A, et al.; INDEED Collaborative Group. Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. Curr Med Res Opin 2009; 25: 1931-40.
24. Grundy SM, Cleeman JI, Daniels SR, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52. (Pubitemid 41532612)
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70. (Pubitemid 29135798)
26. Navaneethan SD, Pansini F, Perkovic V, et al. HMGCoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; 2: CD007784.
27. Agarwal R. Effects of statins and renal function. Mayo Clin Proc 2007; 82: 1381-90.
28. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69. (Pubitemid 37337595)
29. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: 2006-16. (Pubitemid 44036185)
30. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
31. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112: 171-8. (Pubitemid 40982298)
32. Shepherd J, Kastelein JJ, Bittner V, et al.; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007; 2: 1131-9.
33. Shepherd J, Kastelein JJ, Bittner V, et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51: 1448-54. (Pubitemid 351471787)
34. Colhoun HM Betteridge DJ, Durrington PN, et al., CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54: 810-9.
35. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC; Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605-13. (Pubitemid 36687063)
36. Rahman M, Baimbridge C, Davis BR, et al.; ALLHAT Collaborative Research Group. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 2008; 52: 412-24.
37. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC; Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004; 66: 1123-230.
38. Davis TM, Ting R, Best JD, et al.; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54: 280-90.
39. Fellström B, Abedini S, Holdaas H, Jardine AG, Staffler B, Gimpelewicz C; Assessment of Lescol in Renal Transplantation (ALERT) study group. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clin Transplant 2006; 20: 732-9. (Pubitemid 44712274)
40. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 1565-74.
41. Kramer H, Tuttle KR, Leehey D, et al. Obesity management in adults with CKD. Am J Kidney Dis 2009; 53: 151-65.
42. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52: 2867-73. (Pubitemid 37466854)
43. Gabir MM, Hanson RL, Dabelea D, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000; 23: 1113-8.
44. Nang EE, Khoo CM, Tai ES, et al. Is there a clear threshold for fasting plasma glucose that differentiates between those with and without neuropathy and chronic kidney disease: the Singapore Prospective Study Program. Am J Epidemiol 2009; 169: 1454-62.
45. Palmer BF, Fenves AZ. Optimizing blood pressure control in patients with chronic kidney disease. Proc (Bayl Univ Med Cent) 2010; 23: 239-45.
46. Jafar TH, Stark PC, Schmid CH, et al.; the AIPRD Study Group. Progression of chronic kidney disease. The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003; 139: 244-52.
47. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006; 1: 1054-65.
48. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55: 1293-301. (Pubitemid 44354944)
49. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011 Mar 10. [Epub ahead of print].
50. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-97. (Pubitemid 35386908)
51. Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89: 12-7. (Pubitemid 34066579)
52. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-10. (Pubitemid 30257539)
53. Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008; 58: 623-30. (Pubitemid 351294901)
54. Hoieggen A, Alderman MH, Kjeldsen SE, et al.; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-9. (Pubitemid 38251080)
55. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis D. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66: 1714-5. (Pubitemid 39298414)
56. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465-77.
57. Tyroler HA, Ford CE. Serum cholesterol and coronary heart disease risk in female and older hypertensives. The experience under usual community care in the Hypertension Detection and Follow-up Program. Ann Epidemiol 1992; 2: 155-60.
58. Dorresteijn JA, Visseren FL, Ridker PM, et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ 2011 Oct 3; 343: d5888. doi: 10.1136/bmj.d5888.